A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

Inclusion Criteria:

• Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, withactive colitis, ileitis, or ileocolitis, confirmed at any time in the past byclinical, endoscopic, and histologic criteria.

• Participants must have moderately to severely active CD (as defined by a baselinePediatric Crohn's Disease Activity Index [PCDAI] score greater than or equal to [>=]

• Participants must have endoscopy with evidence of active CD defined as SimpleEndoscopic Score for Crohn's Disease (SES-CD) score greater than or equal to (>=) 6 (or >=4 for participants with isolated ileal disease) within 1 month of receivingstudy intervention at Week 0

• Participants must have a history of inadequate response, loss of response, orintolerance to immunomodulators (6-MP, AZA, or MTX), oral or IV corticosteroids, orbiologic therapy/JAK inhibitor therapy; OR have a history of corticosteroiddependence; OR have a history of inadequate response to exclusive enteral nutrition (EEN)

Exclusion Criteria:

• Participants has complications of CD such as symptomatic strictures or stenosis,short gut syndrome, or any other manifestation that might be anticipated to requiresurgery.

• Participants must not have an abscess

• Participants must not have any kind of bowel resection within 26 weeks or any otherintra-abdominal surgery within 12 weeks of baseline